This article is one in a series seeking to give a face to some of the folks at RA Capital Management toiling away tirelessly and passionately to bring the next generation of medicines to patients. 

RA Capital is incredibly proud to have a number of women in senior positions and a deep bench of female biotech and investment leaders. In this piece, Sarah Reed, RA Capital’s general counsel, spoke with just three of the many phenomenal women here who have been involved in some of our recent high-profile exits.

GCEA shows us how to value a medicine not in terms of what you’d pay for the stock but what society should be willing to pay for the product itself. In this article, we perform GCEA for Cidara’s CD388, an anti-flu drug candidate.

The technological renaissance in covalent inhibitor technology over the past decade is impressive. Relatively recent advances in structure-based drug design have unlocked the tantalizing opportunity to engineer covalency into small molecules. Now, RA Capital has incubated and seeded Hyku Biosciences to unlock histidines, tyrosines, and lysines for covalent modification to greatly expand the druggable proteome.